The Efficacy of Boric Acid Used to Treat Experimental Osteomyelitis Caused by Methicillin-Resistant Staphylococcus aureus: an In Vivo Study

Basit Öğe Kaydı
dc.contributor.authorGuzel, Yunus
dc.contributor.authorGolge, Umut H.
dc.contributor.authorGoksel, Ferdi
dc.contributor.authorVural, Ahmet
dc.contributor.authorAkcay, Muruvvet
dc.contributor.authorElmas, Sait
dc.contributor.authorTurkon, Hakan
dc.date.accessioned2025-01-27T20:57:42Z
dc.date.available2025-01-27T20:57:42Z
dc.date.issued2016
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractWe explored the ability of local and systemic applications of boric acid (BA) to reduce the numbers of methicillin-resistant Staphylococcus aureus (MRSA) in a rat model of tibial osteomyelitis (OM), and compared boric acid with vancomycin (V). Implant-associated osteomyelitis was established in 35 rats. After 4 weeks, at which time OM was evident both radiologically and serologically in all animals, the rats were divided into five groups of equal number: group 1, control group (no local application of BA or other medication); group 2, V group; group 3, local BA + V group; group 4, local BA group; and group 5, local + systemic BA group. Serum total antioxidant status, and the levels of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, were measured. Pathological changes attributable to bone OM were evaluated using a grading system. Bacterial colony-forming units (CFUs) per gram of bone were counted. The lowest bacterial numbers were evident in group 3, and the bacterial numbers were significantly lower than that of the control group in all four test groups (p < 0.001). Group 3 also had the least severe bone infection (OM score 1.7 +/- 1.1, p < 0.05). Upon histological and microbiological evaluation, no significant difference was evident between groups 2 and 3. Total antioxidant levels were significantly different in all treatment groups compared to the control group. Microbiological and histopathological evaluation showed that systemic or local application of BA was effective to treat OM, although supplementary V increased the effectiveness of BA.
dc.identifier.doi10.1007/s12011-016-0662-y
dc.identifier.endpage389
dc.identifier.issn0163-4984
dc.identifier.issn1559-0720
dc.identifier.issue2
dc.identifier.pmid26961291
dc.identifier.scopus2-s2.0-84960091543
dc.identifier.scopusqualityQ1
dc.identifier.startpage384
dc.identifier.urihttps://doi.org/10.1007/s12011-016-0662-y
dc.identifier.urihttps://hdl.handle.net/20.500.12428/26456
dc.identifier.volume173
dc.identifier.wosWOS:000383209900016
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherHumana Press Inc
dc.relation.ispartofBiological Trace Element Research
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectOsteomyelitis
dc.subjectAdjunctive therapy
dc.subjectBoric acid
dc.subjectVancomycin
dc.subjectTNF-alpha
dc.subjectIL-6
dc.titleThe Efficacy of Boric Acid Used to Treat Experimental Osteomyelitis Caused by Methicillin-Resistant Staphylococcus aureus: an In Vivo Study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu